<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02166788</url>
  </required_header>
  <id_info>
    <org_study_id>ANZMTG 01.12</org_study_id>
    <secondary_id>ANZMTG 01.12</secondary_id>
    <nct_id>NCT02166788</nct_id>
  </id_info>
  <brief_title>Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma</brief_title>
  <acronym>EAGLE FM</acronym>
  <official_title>Inguinal or Ilio-inguinal Lymphadenectomy for Patients With Metastatic Melanoma to Groin Lymph Nodes and no Evidence of Pelvic Disease on PET/CT Scan - A Randomised Phase III Trial (EAGLE FM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Australia and New Zealand Melanoma Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Council New South Wales</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Melanoma Institute Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Australia and New Zealand Melanoma Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND: Spread of metastatic melanoma to the groin lymph nodes (LN) is a common event
      affecting about 350 people a year in Australia. Globally it has been shown that patients with
      involved groin LN, without proven pelvic LN disease on imaging receive 1 of 3 management
      strategies in equal proportions - inguinal lymphadenectomy (IL); ilio-inguinal
      lymphadenectomy (I-IL); or variable use of either depending on circumstances. Different
      experts have strong and polarised opinions favouring either IL or more extensive I-IL with
      existing cases series reporting conflicting data on best cancer outcomes. No high level
      evidence proves which operation is best. HYPOTHESIS: There will be no significant difference
      in DFS between patients having IL or I-IL, conditional on PET/CT scan showing no evidence of
      pelvic disease at the time of diagnosis of groin LN metastatic melanoma. AIMS: To provide a
      rational evidence base for management for melanoma to the groin LNs by randomly assessing the
      effect of each operation on DFS, distant DFS, overall survival (OS), morbidity - including
      early complications and longer-term rates of lymphedema as well as comprehensively assessed
      QOL. Also to clarify the reliability of PET/CT scans for staging pelvic LNs and evaluate any
      health economic benefits of I-IL over IL. TARGET POPULATION: To recruit 634 patients in 5
      years. DESIGN: An Australian led, international, multi-centre, non-inferiority, phase III,
      prospective, randomised clinical trial comparing IL or I-IL for patients with metastatic
      melanoma to groin LNs and no evidence of pelvic disease on PET/CT. ENDPOINTS: DFS, Distant
      DFS, OS and QOL at 5 years. Accuracy of PET/CT for pelvic LN metastases.

      OUTCOMES: International standardization of care, improved cancer outcomes, improved QOL for
      patients with groin metastatic melanoma. Proof of principle about extent of surgery when
      PET/CT is clear in adjacent LN areas, leading to clinical trials investigating management of
      other lymph node fields.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and Rationale

      Spread of metastatic melanoma to the groin lymph nodes (LN) is a common event for patients
      with melanoma. In melanoma treatment centres around the world, patients without demonstrated
      pelvic LN disease receive 1 of 3 strategies of management in relatively equal proportions
      (Pasquali, Spillane et al. 2012):

      i. Inguinal Lymphadenectomy (IL) ii. Ilio-inguinal Lymphadenectomy (I-IL) iii. Variable use
      of either IL or I-IL surgery.

      Some larger melanoma centres have an institutional policy that all patients have either IL or
      I-IL for metastatic inguinal node involvement. Nearly all centres would agree that patients
      with pelvic LN involvement without distant metastatic disease should have I-IL.

      Study Objectives This study aims to provide a more rational evidence base for appropriate
      management for metastatic melanoma in the groin LNs, through assessing the effect of the
      addition of ipsilateral pelvic lymphadenectomy on patient disease-free survival (DFS),
      distant disease-free survival (DDFS), overall survival (OS), morbidity, and quality of life.
      In addition, the study will clarify the reliability of PET (Positron Emission Tomography) /
      CT (Computed Tomography) scans for staging pelvic LNs, clarify morbidity differences between
      the operations in a balanced cohort, evaluate any health economic benefits of I-IL over IL
      and provide a tissue and serum resource to be used to identify biological markers of
      recurrence and progression after inguinal metastases.

      Study Hypothesis There will be no significant difference in DFS between patients having IL or
      I-IL, conditional on PET/CT scan showing no evidence of pelvic disease at the time of
      diagnosis of groin LN metastatic melanoma.

      Study Population The aim is to recruit 634 patients in 5 years who are 15 years or older with
      cytologically or histologically confirmed metastatic melanoma in inguinal LNs (H&amp;E &amp; IHC);
      specifically with no evidence of pelvic node involvement or distant spread of melanoma
      clinically or on PET/CT staging scans. To be eligible patients must have an Eastern
      Cooperative Oncology Group (ECOG) Performance Status 0-2 at randomisation.

      Study Treatments Eligible patients will be randomised 1:1 to undergo an IL or I-IL.

      Study Design This is an international, multi-centre, phase III, non-inferiority, prospective,
      randomised clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">August 2030</completion_date>
  <primary_completion_date type="Anticipated">August 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of the study will be Disease Free Survival following lymphadenectomy, assessed after 60 months of follow-up.</measure>
    <time_frame>60 Months</time_frame>
    <description>The difference between IL and I-IL surgery in DFS 5 years after randomisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>0 - 120 months</time_frame>
    <description>time from randomisation to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Disease Free Survival</measure>
    <time_frame>0 - 120 Months</time_frame>
    <description>time to new distant melanoma recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional Recurrence Free Survival</measure>
    <time_frame>0 - 120 Months</time_frame>
    <description>time to new regional lymph node recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity differences</measure>
    <time_frame>Up to 120 days from lymphadenectomy, and from 0 - 120 months</time_frame>
    <description>This includes lymphoedema, wound complications (wound infections, dehiscence/necrosis, and seroma) chronic pain, and restriction in mobility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality Of Life</measure>
    <time_frame>0 - 120 Months</time_frame>
    <description>Quality Of Life questionnaires completed by patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity / specificity and positive predictive value and negative predictive value of PET/CT for pelvic disease at diagnosis of groin LN involvement by melanoma.</measure>
    <time_frame>0 - 120 Months</time_frame>
    <description>The diagnostic accuracy of PET/CT and CT for detecting pelvic lymph nodes positive for metastatic melanoma as confirmed by histopathology will be assessed in the sub-group of patients screened and shown to have a positive pelvic LN on PET/CT and those patients who had negative pelvic LN on PET/CT and randomised for I-IL treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource use and utility based Quality Of Life</measure>
    <time_frame>0 - 60 Months</time_frame>
    <description>Resource use will be identified from the trial case report forms, and valued according the relevant Australian Refined Diagnosis Related Groups and Medicare Benefits Schedule item numbers.The cost-effectiveness and cost-utility analyses will calculate total costs and mean per patient costs per surgical group allocation, as well as total and mean benefits per group allocation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">634</enrollment>
  <condition>Metastatic Melanoma to the Groin Lymph Nodes</condition>
  <arm_group>
    <arm_group_label>Arm 1: Inguinal Lymphadenectomy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Inguinal Lymphadenectomy (IL) is removal of the easily accessible superficial groin lymph nodes (LNs) and has a median LN retrieval of 11 lymph nodes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Ilio-inguinal Lymphadenectomy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ilio-inguinal Lymphadenectomy (I-IL) is the removal of the same superficial groin lymp nodes (LN) removed during an IL but also combined with the more surgically complex removal of the ipsilateral pelvic LN. About twice as many LN are removed with I-IL compared to IL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Inguinal Lymphadenectomy</intervention_name>
    <arm_group_label>Arm 1: Inguinal Lymphadenectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ilio-inguinal Lymphadenectomy</intervention_name>
    <arm_group_label>Arm 2: Ilio-inguinal Lymphadenectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients may be included in the study only if they meet all of the following criteria:

          1. Must be 15 and above.

          2. Have primary cutaneous melanoma or if the patient presents with stage III melanoma
             with no known primary tumour then a thorough search for the primary should be
             documented (including perineal and perianal areas)

          3. Life expectancy of at least 10 years from the time of diagnosis, not considering the
             melanoma in question, as determined by the PI

          4. Must have one or multiple inguinal node(s) involved, histologically or cytologically
             proven as metastatic melanoma. This can can be detected:

               -  At the time of diagnosis;

               -  Or by Ultrasound detection;

               -  Or later after relapse when no Sentinel Node Biopsy (SNB) was performed at the
                  time of primary tumour management;

               -  Or as a result of SNB;

               -  Or at the time of regional recurrence after &quot;false negative&quot; SNB;

          5. Absent distant disease clinically and on PET/CT scan. (Patients must have NO further
             distant disease or visceral metastases)

          6. ECOG performance status must be between 0 to 2 at randomisation

          7. Whole body PET/CT scan, specifically stating there is NO evidence of pelvic lymph node
             involvement prior to randomisation and a CT Brain or MRI Brain scan. Scans must be
             performed within 6 weeks prior to randomisation.

          8. Able to provide written, informed consent

          9. Willing to return to the centre for follow up examinations and procedures, as outlined
             in the protocol.

         10. All patients must be randomised and undergo lymphadenectomy surgery no more than 120
             days following diagnosis of inguinal LN involvement

        Exclusion Criteria:

          1. Distant metastatic disease on clinical examination or staging imaging (CT/MRI brain or
             whole body PET/CT scan). Scans must be performed within 6 weeks prior to randomisation

          2. Pelvic LN involvement on SNB or PET/CT scan suggestive of metastatic disease in the
             pelvis - criteria for diagnosis include normal size or enlarged lymph nodes (&gt; 1 cm)
             with increased FDG activity on PET (SUV &gt;3). If there are enlarged, necrotic lymph
             nodes FDG activity on PET is not required to be present. If unsure central review
             should be sought.

          3. Bilateral inguinal lymph node involvement

          4. Patients with a history of major pelvic surgery and / or regional radiotherapy at any
             time in the past

          5. Requiring planned radiotherapy following surgery due to macroscopic, bulky and matted
             nodes.

          6. Unfit for General Anaesthesia

          7. Melanoma-related operative procedures not corresponding to criteria described in the
             protocol

          8. Patients with prior cancers, except:

               -  those with a thin &lt;=1 mm, regionally unrelated melanoma &gt; 5 years ago

               -  those with a good prognosis regionally unrelated cancer (&gt;90% probability of 10
                  years disease specific survival)

               -  other cancers diagnosed more than five years ago with no evidence of disease
                  recurrence within this time

               -  successfully treated basal cell and squamous cell skin carcinoma

               -  carcinoma in-situ of the cervix

               -  1 episode of in transit melanoma &gt; 3 years ago

          9. A medical or psychiatric condition that compromises ability to give informed consent
             or complete the protocol

         10. Positive urine pregnancy test for women of childbearing potential (+/-7 days of
             randomisation onto the trial)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Spillane</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Sydney, Northern Clinical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alex Economides</last_name>
    <phone>+ 61 2 9911 7352</phone>
    <email>eagle.fm@melanoma.org.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Calvary Public Hospital Bruce</name>
      <address>
        <city>Canberra</city>
        <state>Australian Capital Territory</state>
        <zip>2617</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rebecca Read</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia - The Poche Centre</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Economides</last_name>
      <phone>+ 61 2 9911 7352</phone>
      <email>eagle.fm@melanoma.org.au</email>
    </contact>
    <investigator>
      <last_name>Andrew Spillane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sydney Adventist Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2076</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Singh</last_name>
      <email>nina.singh@sah.org.au</email>
    </contact>
    <investigator>
      <last_name>Michael Hughes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julie Howle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Hospital Brisbane</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicky Harvey</last_name>
      <email>vicky.harvey@mater.org.au</email>
    </contact>
    <investigator>
      <last_name>Christopher Allan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Cain</last_name>
      <email>helen.cain@petermac.org</email>
    </contact>
    <investigator>
      <last_name>John Spillane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de CÃ¢ncer de Barretos</name>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camila Crovador</last_name>
      <email>cscrovador@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vinicius Vazquez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.C. Camargo Cancer Center</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01508-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciana Facure Moredo</last_name>
      <email>lufacure@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Joao Duprat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Veneto Institute of Oncology - IOV</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romina Spina</last_name>
      <email>romina.spina@ioveneto.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Sommariva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjan deVries</last_name>
      <email>marjan.devries@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>Hans deWilt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Otis Vrielink</last_name>
      <email>o.m.vrielink@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Barbara van Leeuwen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Peric</last_name>
      <email>bperic@onko-i.si</email>
    </contact>
    <investigator>
      <last_name>Marko Hocevar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adele Cooper</last_name>
      <email>adele.cooper@nnuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Marc Moncrieff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas's Hospitals</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Lombardi</last_name>
      <email>Sara.Lombardi@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Jenny Geh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Slovenia</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://anzmtg.org/trialdetails.aspx?trialno=9</url>
    <description>Trial Website</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2014</study_first_submitted>
  <study_first_submitted_qc>June 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic melanoma</keyword>
  <keyword>groin lymph nodes</keyword>
  <keyword>surgery</keyword>
  <keyword>lymphadenectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

